Arrivent Biopharma Inc

AVBP remains in a Stage 2 advancing uptrend marked by higher highs and higher lows. After a recent pullback into the rising 9/21 EMA band and testing the 50 DMA support area, price has held without signs of exhaustion. Medium-term bias stays Bullish, but short-term execution readiness is Neutral—suggesting patience and selective engagement on pullbacks into EMA and 50 DMA support.

• ↑100% Buy ratings, $44.83 average target signals 33% upside.
• ↑Stock gained 45% since Mar 31 on Phase 3 trial anticipation.
• ↓Negative earnings yield and $160.6 M net loss imply weak profitability.